Clinical Trial Results:
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSS-OVER STUDY FOR EVALUATION OF THE EFFICIENCY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION (5 µG) VIA RESPIMAT® INHALER once a day for 24 weeks for children (6 to 12 years) with bronchopulmonary dysplasia
|
Summary
|
|
EudraCT number |
2020-000529-19 |
Trial protocol |
DE |
Global completion date |
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 Jan 2026
|
First version publication date |
01 Jan 2026
|
Other versions |
|
Summary report(s) |
TUD-TRIBOR-072_2020-000529-19 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.